Drug Search Results
More Filters [+]

GEN-3009

Alternative Names: gen-3009, gen 3009, gen3009, DuoHexaBody-CD37, DuoHexaBodyCD37
Latest Update: 2023-09-12
Latest Update Note: Clinical Trial Update

Product Description

DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32341336/)

Mechanisms of Action: CD37 Antagonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: Genmab

Clinical Description

Map of Global Clinical Trials for GEN-3009

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2019-002752-16

P2

Active, not recruiting

Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

2025-11-17

Recent News Events